SCHEMBL6490058

SCHEMBL6490058

CNc1ccc(-c2ccccc2Br)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
MAPK1 P28482 2/20 0.58
TSHR P16473 2/20 0.46
GFER P55789 1/20 0.41
KIF11 P52732 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
APP P05067 3/20 0.39
MEN1 O00255 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
TP53 P04637 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5141361 0.84 TSHR (0.57) ALDH1A1TSHRGFERKIF11NPC1
SCHEMBL12489603 0.82 ALDH1A1 (0.83) ALDH1A1MAPK1TSHRNPC1RAB9A
SCHEMBL25973862 0.80 TSHR (0.59) ALDH1A1MAPK1TSHRGFERKIF11
SCHEMBL6674385 0.77 CA12 (0.48) TSHRGFERKIF11APPMEN1
SCHEMBL1047461 0.76 ALDH1A1 (0.65) ALDH1A1MAPK1TSHRNPC1RAB9A
SCHEMBL23546571 0.75 TSHR (0.46) ALDH1A1TSHRGFERKIF11APP
SCHEMBL4433057 0.75 CYP2A6 (0.58) MAPK1TSHRGFERKIF11APP
SCHEMBL3786028 0.75 ALDH1A1 (0.58) ALDH1A1TSHRGFERKIF11NPC1
SCHEMBL17504140 0.75 ALDH1A1 (0.47) ALDH1A1TSHRGFERKIF11NPC1
SCHEMBL26029406 0.75 TSHR (0.46) ALDH1A1MAPK1TSHRGFERKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849648-B2 Phenylene alkyne matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-01 US disclosed
EP-1434585-A1 ALKYNE MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2004-07-07 EP disclosed
US-20030144274-A1 Alkyne matrix metalloproteinase inhibitors BUNKER AMY MAE (US) 2003-07-31 US disclosed
WO-2003032999-A1 ALKYNE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2003-04-24 WO disclosed
CN-1023006-C Benzoylurea compounds, process for their production and pesticides contg. them ISHIHARA SANGYO KAISHA (JP) 1993-12-08 CN disclosed
CN-87106674-A Benzoyl urea compound, process for producing the same, and agricultural chemical containing the same 1988-08-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144274-A1 Alkyne matrix metalloproteinase inhibitors MMP11, MMP13, MMP3 ALDH1A1 102/4885MAPK1 108/4885TSHR 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.